Introduction: The incidence of inflammatory bowel disease (IBD) has become a global disease in newly industrialized countries. Inflammation leads to a structural modification in platelets, and the secretion of cytokines results in a change of mean platelet volume (MPV). Aim: To evaluate the relationship between IBD activity parameters and MPV. Materials and methods: The study group included 26 patients [consisting of 18 ulcerative colitis (UC), 6 Crohn\'s disease (CD), and 2 indeterminate colitis patients] followed-up at Dr. Behçet Uz Children\'s Hospital between 2004 and 2016. The data of patients were screened retrospectively and the demographic, clinical and laboratory characteristics were evaluated. The changes in MPV during the activation, remission and relapse periods of the disease and correlation with other disease activity markers were investigated. Results: The study group consisted of 26 IBD patients (female/male: 11/15) and 71 healthy controls. We used the Pediatric Ulcerative Colitis Activity Index and the Pediatric Crohn\'s Disease Activity Index to determine disease activity. The IBD group had statistically significantly higher leukocyte count and lower hemoglobin values compared with the control group (p = 0.05). The mean platelet count and MPV values were not correlated significantly with both the C-reactive protein level and erythrocyte sedimentation rate (p > 0.05). Conclusion: We suggest that MPV is a simple and inexpensive method that can be useful in the diagnosis of IBD but does not provide significant results to determine the disease activity.
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017;390(10114):P2769–P2778. DOI: 10.1016/S0140-6736(17)32448-0pii:S0140-6736(17)32448-0.
Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006;55(3):426–431. DOI: 10.1136/gut.2005.069476.
Platelet-derived CXC chemokines: old players in new games. Immunol Rev 2000;177(1):204–216. DOI: 10.1034/j.1600-065X.2000.17705.x.
Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am J Gastroenterol 2001;96(3):776–781. DOI: 10.1111/j.1572-0241.2001.03621.x.
An overlooked indicator of disease activity in ulcerative colitis: mean platelet volume. Platelets 2009;20(4):277–281. DOI: 10.1080/09537100902856781.
Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease a population-based study. Aliment Pharmacol Ther 2011;34(10):1217–1224. DOI: 10.1111/j.1365-2036.2011.04857.x.
Thrombocytosis in chronic inflammatory bowel disease. Ann Intern Med 1968;68(5):1013–1021. DOI: 10.7326/0003-4819-68-5-1013.
Thrombocytosis in ulcerative colitis and Crohn's disease. Scand J Gastroenterol 1973;8:135–138.
Haemostatic system in inflammatory bowel diseases: New players in gut inflammation. World J Gastroenterol 2011;17(5):594–608. DOI: 10.3748/wjg.v17.i5.594.
Size dependent platelet subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity, and function. Br J Haematol 1982;50(3):509–519. DOI: 10.1111/j.1365-2141.1982.tb01947.x.
The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001;85(03):430–434. DOI: 10.1055/s-0037-1615600.
Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology 1994;106(4):840–845. DOI: 10.1016/0016-5085(94)90741-2.
Thromboembolism in inflammatory bowel disease: role of platelets. Gut 1993;34(2):247–251. DOI: 10.1136/gut.34.2.247.
Mucosal capillary thrombi in rectal biopsies. Histopathology 1992;21(2):127–133. DOI: 10.1111/j.1365-2559.1992.tb00360.x.
Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci USA 2000;97(13):6930–6932. DOI: 10.1073/pnas.97.13.6930.
Evidence for activation of platelets in the syn-ovial fluid from patients with rheumatoid arthritis. Rheumatol Int 1989;9(1):19–24. DOI: 10.1007/BF00270285.
Platelet activation markers and soluble adhesion molecules in patients with systemic lupus erythematosus. Autoimmunity 2001;33(2):85–94. DOI: 10.3109/08916930108995993.
Immunohistochemical study of tissue factor expressioning normal intestine and idiopathic inflammatory bowel disease. J Clin Pathol 1993;46(8):703–708. DOI: 10.1136/jcp.46.8.703.
Early mucosal changes in Crohn's disease. Gut 1993;34(3):375–381. DOI: 10.1136/gut.34.3.375.
Platelet density and size in inflammatory bowel disease. Thromb Haemost 1996;75(04):560–561. DOI: 10.1055/s-0038-1650321.
Biological markers in inflammatory bowel disease: practical consideration for clinicians. Gastroenterol Clin Biol 2009;33(Suppl 3):S158–S173. DOI: 10.1016/S0399-8320(09)73151-3.
Radford-smith: clinically active Crohn's disease in the presence of a low C-reactive protein. Scand J Gastroenterol 2006;41(3):306–311. DOI: 10.1080/00365520500217118.
Use of C-reactive protein in children with newly diagnosed inflammatory bowel disease. J Pediatr 2011;159(2):340–342. DOI: 10.1016/j.jpeds.2011.04.028.